Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 16 Jan 2018
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
3 days ago
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
4 days ago
It appears that urgent repeat endoscopic retrograde cholangiopancreatography (ERCP) predicts failure of plastic stent treatment for biliary strictures (BS) following liver transplant, according to a study.

Time to retreatment in eyes with nAMD after pause in therapy

16 Dec 2016

A recent study offers times to retreatment in eyes with neovascular age-related macular degeneration (nAMD) that has been treatment-free for intervals of 3 to 12 months and demonstrates the likelihood of repeat therapy within the next year even after a treatment-free interval (TFI) of 12 months.

Researchers conducted a multicentre national nAMD database study to identify time to retreatment in eyes with nAMD that had been treatment-free for intervals of 3, 6, 9 and 12 months during the maintenance phase of ranibizumab therapy within the UK National Health Service. They collected structured data from 14 centres, involving 12,951 eyes receiving 92,976 ranibizumab injections.

Three fixed, monthly infection in a loading phase of treatment were administered to patients, followed by a pro re nata retreatment regimen in a maintenance phase. Eyes with TFI of 3, 6, 9 and 12 months in the maintenance phase were identified and the time to retreatment after these TFIs was determined.

For the 20th and 50th centiles, the time to retreatment was 0.58/2.54 months after a 3-month TFI, 2.07/9.62 months after a 6-month TFI, 3.69/15.84 months after a 9-month TFI and 5.90/22.49 months after a 12-month TFI.

Following a TFI of 3, 6, 9 and 12 months, respective retreatments were required for 68, 44, 31 and 21 percent of eyes after an additional 6 months of follow-up. Likewise, 77, 56, 43 and 34 percent of these eyes needed retreatment after 12 months of follow-up.

These findings can help plan appropriate follow-up intervals for patients who have been treatment-free for an interval of up to 1 year, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 16 Jan 2018
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
3 days ago
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
4 days ago
It appears that urgent repeat endoscopic retrograde cholangiopancreatography (ERCP) predicts failure of plastic stent treatment for biliary strictures (BS) following liver transplant, according to a study.